Literature DB >> 7699327

Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.

I Hauber1, H Gulle, H M Wolf, M Maris, H Eggenbauer, M M Eibl.   

Abstract

Major histocompatibility complex (MHC) class II deficiency is an inherited autosomal recessive combined immunodeficiency. The disease is known as bare lymphocyte syndrome (BLS). BLS is characterized by a lack of constitutive MHC class II expression on macrophages and B cells as well as a lack of induced MHC class II expression on cells other than professional antigen-presenting cells (APCs) due to the absence of mRNA and protein of the human leukocyte antigen (HLA) class II molecules, designated HLA-DR, -DQ, and -DP. The defect in gene expression is located at the transcriptional level and affects all class II genes simultaneously. Here we have analyzed transcription and protein expression of class II antigens in Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines and mononuclear cells (MNCs) of twin brothers. Whereas flow cytometric analysis failed to detect class II antigens on the cell surface of the patients' EBV-B cells and MNCs, examination of the genes coding for HLA-DR, -DQ, -DP, and the invariant chain (Ii) by reverse transcriptase-polymerase chain reaction amplification resulted in an unusual mRNA pattern in the B cell lines of the patients (HLA-DR alpha +, -DR beta, -DQ alpha +, -DQ beta -, -DP alpha -; -DP beta +, Ii+). In accordance with these findings no HLA-DR beta-specific protein was detected by immunoblotting, whereas low levels of HLA-DR alpha and normal levels of Ii were present. In contrast to EBV-B cells, the MNCs of both patients displayed a residual HLA-DR beta, -DQ beta, and -DP alpha mRNA signal. Furthermore, HLA-DR beta-specific protein was found in addition to HLA-DR alpha by immunoblotting of cell lysates, even though it was clearly decreased as compared with controls. Our results indicate that the defect in class II antigen expression is not necessarily present to the same extent in B cells and cells of other lineages. mRNA levels of HLA-DR beta were found to be enriched in adherent cells within the MNC fraction. Further investigations indicated that the MHC class II expressed is functional in antigen presentation, as the two boys' CD4+ T cells became activated and expressed interleukin-2R after stimulation of peripheral blood mononuclear cell cultures with recall antigen (tetanus toxoid). Furthermore, T cells tested in one of the two patients responded to both MHC class I and II allostimulation, and this response was inhibited by monoclonal antibodies of the respective specificity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699327      PMCID: PMC2191976          DOI: 10.1084/jem.181.4.1411

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  54 in total

1.  Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation.

Authors:  C V Harding; E R Unanue
Journal:  Nature       Date:  1990-08-09       Impact factor: 49.962

Review 2.  Quantitation of RNA using the polymerase chain reaction.

Authors:  K P Foley; M W Leonard; J D Engel
Journal:  Trends Genet       Date:  1993-11       Impact factor: 11.639

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

Review 4.  MHC class II antigen processing: biology of invariant chain.

Authors:  A J Sant; J Miller
Journal:  Curr Opin Immunol       Date:  1994-02       Impact factor: 7.486

5.  Brief report: twin boys with major histocompatibility complex class II deficiency but inducible immune responses.

Authors:  H M Wolf; I Hauber; H Gulle; V Thon; H Eggenbauer; M B Fischer; S Fiala; M M Eibl
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

6.  Structure and nucleotide sequence of the heavy chain gene of HLA-DR.

Authors:  H K Das; S K Lawrance; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

7.  T cell differentiation and generation of the antigen-specific T cell repertoire in man: observations in MHC class II deficiency.

Authors:  J W Mannhalter; H M Wolf; I Hauber; M Miricka; H Gadner; M M Eibl
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

8.  Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome.

Authors:  C Klein; B Lisowska-Grospierre; F LeDeist; A Fischer; C Griscelli
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

9.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

Authors:  V Steimle; C A Siegrist; A Mottet; B Lisowska-Grospierre; B Mach
Journal:  Science       Date:  1994-07-01       Impact factor: 47.728

10.  Complete sequence of an HLA-dR beta chain deduced from a cDNA clone and identification of multiple non-allelic DR beta chain genes.

Authors:  E O Long; C T Wake; J Gorski; B Mach
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  9 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.

Authors:  T Scholl; S K Mahanta; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Identification of the transcription factors NF-YA and NF-YB as factors A and B that bound to the promoter of the major histocompatibility complex class II gene I-A beta.

Authors:  A Celada; S R McKercher; R A Maki
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

5.  Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.

Authors:  John Sidney; Amiyah Steen; Carrie Moore; Sandy Ngo; Jolan Chung; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

6.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

7.  A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population.

Authors:  Denise M McKinney; Scott Southwood; Denise Hinz; Carla Oseroff; Cecilia S Lindestam Arlehamn; Veronique Schulten; Randy Taplitz; David Broide; Willem A Hanekom; Thomas J Scriba; Robert Wood; Rafeul Alam; Bjoern Peters; John Sidney; Alessandro Sette
Journal:  Immunogenetics       Date:  2013-02-08       Impact factor: 2.846

8.  A cis-eQTL of HLA-DPB1 Affects Susceptibility to Type 1 Autoimmune Hepatitis.

Authors:  Tomoo Yamazaki; Takeji Umemura; Satoru Joshita; Kaname Yoshizawa; Eiji Tanaka; Masao Ota
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

9.  Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains.

Authors:  J Douhan; I Hauber; M M Eibl; L H Glimcher
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.